Fascin is Secreted in Male’s Serum: Results of a Pilot Study

Porav-Hodade, Daniel; Martha, Orsolya; Bălan, Daniel; Tătaru, Octavian Sabin; Huţanu, Adina; Sin, Anca; Vartolomei, Mihai Dorin

doi:10.4155/fsoa-2017-0098

Cited by 3 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we found a positive correlation between FSCN1 levels measured in serum and in the primary ACC mass. The levels found in non-tumoral patients in our studies are in agreement with those reported in similar studies performed in healthy subjects (13) and in other cancers (14) and lower than 10 ng/ml. Moreover, serum FSCN1 levels were significantly higher in ACC patients compared with obese/T2D patients, who have higher levels of FSCN1, probably due to kidney overload/damage associated to diabetes, as already demonstrated in renal injury associated with renal transplantation (15).…”

Section: Discussionsupporting

confidence: 93%

Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer

et al. 2021

View full text Add to dashboard Cite

Fascin-1 (FSCN1) is an actin-bundling protein associated with an invasive and aggressive phenotype of several solid carcinomas, as it is involved in cell cytoskeleton rearrangement and filopodia formation. Adrenocortical carcinoma (ACC) is a rare endocrine malignancy characterized by poor prognosis, particularly when metastatic at diagnosis. Radical resection is the only therapeutic option for ACC patients in addition to the adjuvant treatment with mitotane. Novel specific biomarkers suggestive of tumor progression to refine diagnosis and prognosis of patients with advanced ACC are urgently needed. ACC intratumoral FSCN1 has previously been suggested as a valid prognostic marker. In the present study, we identified FSCN1 in the bloodstream of a small cohort of ACC patients (n = 27), through a specific ELISA assay for human FSCN1. FSCN1 can be detected in the serum, and its circulating levels were evaluated in pre-surgery samples, which resulted to be significantly higher in ACC patients from stage I/II and stage III/IV compared with nontumoral healthy controls (HC, n = 4, FI: 5.5 ± 0.8, P<0.001, and 8.0 ± 0.5, P < 0.001 for stage I/II and stage III/IV group vs HC, respectively). In particular, FSCN1 levels were significantly higher in advanced stage versus stage I/II (22.8 ± 1.1 vs 15.8 ± 1.8 ng/ml, P < 0.005, respectively). Interestingly, circulating levels of pre-surgical FSCN1 can significantly predict tumor progression/recurrence (Log rank = 0.013), but not the overall survival (Log rank=0.317), in patients stratified in high/low PreS FSCN1. In conclusion, these findings—though very preliminary—suggest that circulating FSCN1 may represent a new minimally-invasive prognostic marker in advanced ACC, in particular when measured before surgery enables histological diagnosis.

show abstract

Section: Discussionsupporting

confidence: 93%

Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Our results showed that serum levels of FSCN1 did not differ between PCa patients and controls, and these findings are in accordance with the results of data mining performed on TCGA-PRAD dataset. In contrast, similar serum FSCN1 determinations, performed in patients diagnosed with lung cancer, laryngeal carcinoma and hepatocellular carcinoma, were correlated to tumor aggressiveness [ 32 , 38 , 49 ]. Teng et al were the first to investigate serum FSCN1 in patients with cancer, utilizing an ELISA kit for human FSCN1 from USCN Life Science (TX, USA) and reporting higher values in patients with NSCLC compared with healthy controls (which reported a median value of 3 ng/ml) [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

“…As results, our mean FSCN1 serum level reported for healthy controls was 7.33 ng/ml. However, normal FSCN1 serum levels were shown to be 9.43 ng/ml, in a recently published article [ 49 ]. Similarly, FSCN1 serum levels identified by Elewa et al in healthy males was 9.9 ng/ml while patients with hepatocellular carcinoma showed a mean FSCN1 serum level of 14.8 ng/ml which was significantly higher compared with levels reported in controls and in cirrhotic participants [ 49 , 57 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, normal FSCN1 serum levels were shown to be 9.43 ng/ml, in a recently published article [ 49 ]. Similarly, FSCN1 serum levels identified by Elewa et al in healthy males was 9.9 ng/ml while patients with hepatocellular carcinoma showed a mean FSCN1 serum level of 14.8 ng/ml which was significantly higher compared with levels reported in controls and in cirrhotic participants [ 49 , 57 ]. However, also in those cases, methodologies were different as FSCN1 serum levels were determined utilizing different ELISA kits.…”

Section: Discussionmentioning

confidence: 99%

“…In order to evaluate FSCN1 serum levels, a quantitative sandwich ELISA method was used, following the manufacturer’s instructions (US Biological, Human Fascin, MA, USA), with a detection range of 0.312–20 ng/ml. After blood collection, the tubes were allowed to clot and centrifuged at 3500 rpm Serum was aliquoted and stored at -80°C, and successively analyzed on automated DSX Dynex ELISA System (Dynex Technology, VA, USA) [ 49 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Fascin-1 and Its Role As a Serological Marker in Prostate Cancer: a Prospective case–control Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.

show abstract

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Zhang,

Bian,

Gao

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Human cancer statistics show that an increased incidence of urologic cancers such as bladder cancer, prostate cancer, and renal cell carcinoma. Due to the lack of early markers and effective therapeutic targets, their prognosis is poor. Fascin-1 is an actin-binding protein, which functions in the formation of cell protrusions by cross-linking with actin filaments. Studies have found that fascin-1 expression is elevated in most human cancers and is related to outcomes such as neoplasm metastasis, reduced survival, and increased aggressiveness. Fascin-1 has been considered as a potential therapeutic target for urologic cancers, but there is no comprehensive review to evaluate these studies. This review aimed to provide an enhanced literature review, outline, and summarize the mechanism of fascin-1 in urologic cancers and discuss the therapeutic potential of fascin-1 and the possibility of its use as a potential marker. We also focused on the correlation between the overexpression of fascin-1 and clinicopathological parameters. Mechanistically, fascin-1 is regulated by several regulators and signaling pathways (such as long noncoding RNA, microRNA, c-Jun N-terminal kinase, and extracellular regulated protein kinases). The overexpression of fascin-1 is related to clinicopathologic parameters such as pathological stage, bone or lymph node metastasis, and reduced disease-free survival. Several fascin-1 inhibitors (G2, NP-G2-044) have been evaluated in vitro and in preclinical models. The study proved the promising potential of fascin-1 as a newly developing biomarker and a potential therapeutic target that needs further investigation. The data also highlight the inadequacy of fascin-1 to serve as a novel biomarker for prostate cancer.

show abstract

Fascin is Secreted in Male’s Serum: Results of a Pilot Study

Cited by 3 publications

References 17 publications

Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer

Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer

Fascin-1 and Its Role As a Serological Marker in Prostate Cancer: a Prospective case–control Study

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Contact Info

Product

Resources

About